Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Health
  • Music
  • Business
  • Technology
  • Financial
  • Real Estate
ncarol.com

Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
ncarol.com/10114932

Trending...
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.

"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."

Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of  Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.

"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."

More on ncarol.com
  • CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets
  • Custom Disposables - Wholesale Packaging Solutions for restaurants, food chains, and food distributors
  • California Security Glass is an affordable bulletproof glass installation company in LA serving a variety of neighboring cities
  • Allstream Energy Partners Announce Media Partnership with the 2026 EPC Show - The Energy Projects Conference
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry

Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.

About Isosceles Pharmaceuticals, Inc.

Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.

Investor Contact
Brett Lanier
[email protected]

SOURCE Isosceles Pharmaceuticals, Inc.

Related Links

www.isoscelespharma.com
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Brilliant Minds to Gather in Fort Worth for National Mensa Event
  • Drivin N Cryin at 40: A Spit Shine that Sparkles Differently | Visulite | June 12, 2026 | by Derek Farley
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • A Healthier Home Publishes New EnviroVention™ E-Book
  • Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
  • Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
  • New Children's Book Celebrates the Limb Difference Community
  • TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
  • High Point Girl Scout Troop Helps Transform Community Garden at Senior Living Community
  • Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
  • Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
  • Tickets now available for October 3rd Awadagin Pratt concert at the Tryon Fine Arts Center
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • New from Regal House Publishing, Shout at the Thunder, a girl reveals secrets in a forgotten mansion
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • WOOX Debuts Elegante Sporter and Hybrid Stocks for Remington 700, Ruger 10/22, and Ruger American Gen II Rifles
_catLbl0 _catLbl1

Popular on ncarol.com

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 291
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA - 121
  • Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM - 110
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
  • Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
  • Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology

Similar on ncarol.com

  • Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute